Metadherin: A Therapeutic Target in Multiple Cancers.
cancer
chemoresistance
immunotherapy
metadherin
microRNA
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
02
2019
accepted:
15
04
2019
entrez:
28
5
2019
pubmed:
28
5
2019
medline:
28
5
2019
Statut:
epublish
Résumé
Altered expression of many genes and proteins is essential for cancer development and progression. Recently, the affected expression of metadherin (MTDH), also known as AEG-1 (Astrocyte Elevated Gene 1) and Lyric, has been implicated in various aspects of cancer progression and metastasis. Elevated expression of MTDH/AEG-1 has been reported in many cancers including breast, prostate, liver, and esophageal cancers, whereas its expression is low or absent in non-malignant tissues. These expression studies suggest that MTDH may represent a potential tumor associated antigen. MTDH also regulates multiple signaling pathways including PI3K/Akt, NF-κB, Wnt/β-catenin, and MAPK which cooperate to promote the tumorigenic and metastatic potential of transformed cells. Several microRNA have also been found to be associated with the increased MTDH expression in different cancers. Increased MTDH levels were linked to the tumor chemoresistance making it an attractive novel therapeutic target. In this review, we summarize data on MTDH function in various cancers.
Identifiants
pubmed: 31131259
doi: 10.3389/fonc.2019.00349
pmc: PMC6509227
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
349Références
Cancer Cell. 2004 Apr;5(4):365-74
pubmed: 15093543
Exp Cell Res. 2004 Oct 15;300(1):134-48
pubmed: 15383321
Gene. 2005 Jun 20;353(1):8-15
pubmed: 15927426
Cancer Res. 2006 Feb 1;66(3):1509-16
pubmed: 16452207
Mol Cell. 2007 Apr 13;26(1):75-87
pubmed: 17434128
Oncogene. 2007 Dec 6;26(55):7647-55
pubmed: 17563745
Gastroenterology. 2007 Jun;132(7):2557-76
pubmed: 17570226
Oncogene. 2008 Feb 14;27(8):1114-21
pubmed: 17704808
Cancer Res. 2008 Mar 1;68(5):1478-84
pubmed: 18316612
Cancer Cell. 2009 Jan 6;15(1):9-20
pubmed: 19111877
J Exp Clin Cancer Res. 2009 Feb 15;28:19
pubmed: 19216799
J Clin Invest. 2009 Mar;119(3):465-77
pubmed: 19221438
Clin Cancer Res. 2009 May 1;15(9):3003-13
pubmed: 19383828
Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21300-5
pubmed: 19940250
Diagn Pathol. 2010 Jun 18;5:38
pubmed: 20565850
Cancer Immunol Immunother. 2011 Jun;60(6):883-93
pubmed: 21400023
PLoS One. 2011;6(6):e20920
pubmed: 21687633
Clin Cancer Res. 2011 Nov 1;17(21):6693-701
pubmed: 21908579
Clin Cancer Res. 2011 Dec 1;17(23):7294-302
pubmed: 21976539
Clin Cancer Res. 2011 Dec 15;17(24):7539-50
pubmed: 22031094
J Transl Med. 2011 Dec 01;9:205
pubmed: 22133054
J Biol Chem. 2012 Feb 10;287(7):4485-91
pubmed: 22199357
Oncol Rep. 2012 Jun;27(6):2073-9
pubmed: 22470125
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Transl Med. 2012 May 29;10:109
pubmed: 22643064
Oncol Lett. 2012 Aug;4(2):319-323
pubmed: 22844377
Breast Cancer. 2014 May;21(3):341-9
pubmed: 22903204
Gut Liver. 2013 Mar;7(2):206-12
pubmed: 23560157
Tumour Biol. 2013 Aug;34(4):2433-40
pubmed: 23595222
Adv Cancer Res. 2013;120:135-57
pubmed: 23889990
Mol Cancer. 2013 Sep 24;12(1):109
pubmed: 24063540
Tumour Biol. 2014 Jul;35(7):6679-85
pubmed: 24705862
Cell Physiol Biochem. 2014;33(5):1557-67
pubmed: 24854844
Br J Cancer. 2014 Jul 15;111(2):355-64
pubmed: 24918821
Mol Med Rep. 2015 Jan;11(1):454-60
pubmed: 25323629
Oncotarget. 2014 Nov 15;5(21):10816-29
pubmed: 25333261
BMC Cancer. 2014 Nov 24;14:869
pubmed: 25417825
Cancer Lett. 2015 Feb 1;357(1):384-392
pubmed: 25434799
Med Oncol. 2015 Feb;32(2):479
pubmed: 25575438
Medicine (Baltimore). 2015 Feb;94(6):e502
pubmed: 25674742
Int J Oncol. 2015;46(6):2459-66
pubmed: 25902416
Cancer Cell Int. 2015 Apr 02;15:38
pubmed: 25960691
PLoS One. 2015 May 19;10(5):e0127599
pubmed: 25993398
Int J Clin Exp Med. 2015 Apr 15;8(4):4795-807
pubmed: 26131054
Cancer Res. 2015 Sep 1;75(17):3672-80
pubmed: 26141861
Oncotarget. 2016 Jan 12;7(2):1288-99
pubmed: 26595523
Oncotarget. 2016 Jan 26;7(4):4559-69
pubmed: 26683226
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
Microbiol Immunol. 2016 Sep;60(9):646-52
pubmed: 27554419
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783
pubmed: 27899578
Nat Rev Cancer. 2017 Apr;17(4):209-222
pubmed: 28233802
Oncol Res. 2017 Nov 2;25(9):1505-1515
pubmed: 28276315
Int J Oncol. 2017 Jul;51(1):63-74
pubmed: 28534938
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):
pubmed: 28710258
Int J Oncol. 2017 Sep;51(3):812-822
pubmed: 28731152
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
RNA. 2018 May;24(5):688-703
pubmed: 29438049
Oncogene. 2018 Nov;37(47):6166-6179
pubmed: 30002443
Saudi J Biol Sci. 2018 Jul;25(5):975-981
pubmed: 30108450
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593